A method of staging a disease caused by a human papillomavirus infection in a human subject, comprising: (i) conducting an immunological assay on a cervical clinical sample of the human subject; and (ii) obtaining a staining of one or more human cells from the clinical sample using one or more monoclonal antibodies generated against one or more purified recombinant papillomavirus proteins in a native conformation, wherein the one or more monoclonal antibodies are capable of binding one or more human papillomavirus viral proteins selected from the group consisting of: HPV E6 proteins, HPV E7 proteins, and a combination thereof, wherein the human papillomavirus viral proteins are associated with a HPV type selected from the group consisting of: HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV39, HPV44, HPV45, HPV51, HPV52, HPV53, HPV58, HPV59, HPV66, HPV68, (iii) detecting a location of the staining the sample of cells, said cells having a nuclear portion and a cytoplasmic portion; and (iv) determining the stage of the disease caused by papillomavirus infection based on the location of the staining of the cell by comparing the staining of the nuclear portion to the staining of the cytoplasmic portion of the the one or more human cells from the clinical sample, wherein the stage of the disease is early, if the location of the staining in the dysplasia cell is in the nuclear portion, wherein the early stage of the disease is selected from the group consisting of: an early dysplasia stage, low-grade squamous intracervical lesion (LSIL), high grade squamous intracervical lesion (HSIL), and cervical intraneoplasm (CIN1, CIN2); and the stage of the disease is late, if the location of the staining in the dysplasia cell is in both the nuclear portion and the cytoplasmic portion, wherein the late stage of the disease is selected from the group consisting of: cervical intraneoplasm (CIN2, CIN3), invasive cervical cancer, squamous cell carcinoma, and adenocarcinoma. (i) conducting an immunological assay on a cervical clinical sample of the human subject; and (ii) obtaining a staining of one or more human cells from the clinical sample using one or more monoclonal antibodies generated against one or more purified recombinant papillomavirus proteins in a native conformation, wherein the one or more monoclonal antibodies are capable of binding one or more human papillomavirus viral proteins selected from the group consisting of: HPV E6 proteins, HPV E7 proteins, and a combination thereof, wherein the human papillomavirus viral proteins are associated with a HPV type selected from the group consisting of: HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV39, HPV44, HPV45, HPV51, HPV52, HPV53, HPV58, HPV59, HPV66, HPV68, the one or more monoclonal antibodies are capable of binding one or more human papillomavirus viral proteins selected from the group consisting of: HPV E6 proteins, HPV E7 proteins, and a combination thereof, wherein the human papillomavirus viral proteins are associated with a HPV type selected from the group consisting of: HPV6, HPV11, HPV16, HPV18, HPV31, HPV33, HPV39, HPV44, HPV45, HPV51, HPV52, HPV53, HPV58, HPV59, HPV66, HPV68, (iii) detecting a location of the staining the sample of cells, said cells having a nuclear portion and a cytoplasmic portion; and (iv) determining the stage of the disease caused by papillomavirus infection based on the location of the staining of the cell by comparing the staining of the nuclear portion to the staining of the cytoplasmic portion of the the one or more human cells from the clinical sample, wherein the stage of the disease is early, if the location of the staining in the dysplasia cell is in the nuclear portion, wherein the early stage of the disease is selected from the group consisting of: an early dysplasia stage, low-grade squamous intracervical lesion (LSIL), high grade squamous intracervical lesion (HSIL), and cervical intraneoplasm (CIN1, CIN2); and the stage of the disease is late, if the location of the staining in the dysplasia cell is in both the nuclear portion and the cytoplasmic portion, wherein the late stage of the disease is selected from the group consisting of: cervical intraneoplasm (CIN2, CIN3), invasive cervical cancer, squamous cell carcinoma, and adenocarcinoma. the stage of the disease is early, if the location of the staining in the dysplasia cell is in the nuclear portion, wherein the early stage of the disease is selected from the group consisting of: an early dysplasia stage, low-grade squamous intracervical lesion (LSIL), high grade squamous intracervical lesion (HSIL), and cervical intraneoplasm (CIN1, CIN2); and the stage of the disease is late, if the location of the staining in the dysplasia cell is in both the nuclear portion and the cytoplasmic portion, wherein the late stage of the disease is selected from the group consisting of: cervical intraneoplasm (CIN2, CIN3), invasive cervical cancer, squamous cell carcinoma, and adenocarcinoma.